GLP-1 receptor agonists such as semaglutide and tirzepatide are FDA-regulated for chronic weight management in adults with a BMI of 30 or higher, or 27 with a weight-related condition. Las Vegas runs around the clock, and dealers, servers, performers and resort staff working overnight and rotating shifts rarely fit a daytime clinic into their week - even as the job keeps appearance and stamina front of mind. Telehealth works on their clock: a licensed Nevada physician reviews your online assessment under Nevada Revised Statutes §629.515, and compounded medication from an FDA-registered 503B pharmacy ships to your Las Vegas address. Monthly cost runs $199–$379 versus about $1,247 for brand-name Ozempic or Wegovy. Medical Director: Dr. Steven Nguyen, MD, Board-Certified Internal Medicine. Serving Las Vegas ZIP codes: 89101, 89102, 89104, 89109, 89119.
Local clinics serving Michael Way: Premier Physicians Weight Loss & Wellness, Medical Reducing Inc and We Do Care Weight Loss. Many patients compare these in-person options against licensed GLP-1 telehealth — prescribed online, shipped to the door.
Tirzepatide seen from Michael Way, without the jargon. Tirzepatide is the newest and most potent molecule in the incretin class: it is the first approved dual GIP/GLP-1 agonist, often chosen when semaglutide plateaus.
The most common effects are digestive and temporary: nausea, early fullness, altered bowel habits, especially during the titration phase. A small share of patients stop due to intolerance; for most, the discomfort stays manageable and temporary.
Tirzepatide belongs to the 'Dual GIP + GLP-1 agonist (first twincretin molecule)' class and is given as a weekly subcutaneous injection. In this state, Nevada Revised Statutes §629.515; the reference body is Nevada State Board of Medical Examiners. Typical dosing: 2.5 - 5 - 7.5 - 10 - 12.5 - 15 mg/week, stepped up by tolerance and goal. Around Michael Way in Clark County, 3 weight-management practice(s) are listed locally.
Generally no: they are most pronounced early in treatment and during dose increases, then ease off.
In the SURMOUNT head-to-head trials, tirzepatide produced greater average weight loss, likely thanks to its dual GIP + GLP-1 action. Response is individual and should be assessed by a physician.
Yes: both are tirzepatide. Mounjaro is dosed/labeled for type 2 diabetes, Zepbound for weight management.
Medical Director: Dr. Steven Nguyen, MD, Board-Certified Internal Medicine. Licensed in Nevada. All prescriptions issued under Nevada Revised Statutes §629.515 and supervised by Nevada State Board of Medical Examiners.